GCP Blog

August 2026 Edition 101 pieces in print

The Lead Story

№101

GCPAugust 18, 202612 min read

The Clinical Research Coordinator as a GCP-Accountability Map: Which CRC Duties Carry Regulatory Weight Under ICH E6(R3) and 21 CFR 312

If you are an early-career coordinator, you have read a dozen pages that list what a CRC does. This one does something different. It treats each duty as a line item in a GCP-accountability map: the task you perform, the regulation that makes it mandatory, and the part of that obligation the principal investigator can never hand off. Read this way, your job stops being a list of chores and becomes a map of where your accountability ends and the PI's begins.

Read the full piece

Recent dispatches

GCPAugust 17, 2026

EDC, eCRF, eCOA and IWRS as One Regulated Data Flow: Who Owns the Source Record and Where ALCOA Breaks at the Seams

Five acronyms recur on every modern study, and practitioners are routinely asked to "define the difference" as if it were trivia.

Read

GCPAugust 14, 2026

Clinical Trial Design and Management as One Quality-by-Design Chain: From Critical-to-Quality Factors to Risk-Based Oversight

This is the pillar for clinical-operations leads, study managers, and CRAs who are scoping a new trial or onboarding to one.

Read

GCPAugust 13, 2026

Clinical Trial Site Monitoring: The Visit-Type Lifecycle (SSV, SIV, IMV, COV) and the SIV Enrollment Gate

Site monitoring gets flattened in everyday conversation into "the CRA visit," as though every trip to a site is interchangeable.

Read

GCPAugust 12, 2026

The TMF Reference Model as a Tailoring Exercise: Mapping DIA/CDISC Zones to ICH E6(R3) Essential Records

The DIA TMF Reference Model is a community-built taxonomy that organizes the essential documents of a clinical trial into a consistent Zone > Section > Artifact hierarchy (commonly cited as 11 zones, roughly 48 sections, and around 250 artifacts, with a sub-artifact layer added in v3.2).

Read

GCPAugust 11, 2026

Clinical Trial Close-Out Checklist: A Dependency-Gated Sequence Built on GCP and 21 CFR Part 312

Most published close-out checklists hand you the CASPER-style alphabetical pile of documents and stop at the visit.

Read

GCPAugust 10, 2026

The Monitoring Visit Report as Oversight Evidence: A GCP-Audit-Ready MVR, Not a Filled-In Form

Most teams treat the MVR as a form: date, attendees, what was reviewed, a box for issues, file it, move on.

Read

GCPAugust 7, 2026

Data Safety Monitoring Plan vs. Medical Monitoring Plan vs. DSMB Charter: Which One Your Trial Needs, Who Signs It, and How They Fit Together

A coordinator handed a new protocol and told to "produce the safety monitoring plan" usually starts from a downloaded NIH or academic PDF that conflates three different documents.

GCP Blog — Field notes from clinical research

The Lead Story

The Clinical Research Coordinator as a GCP-Accountability Map: Which CRC Duties Carry Regulatory Weight Under ICH E6(R3) and 21 CFR 312

Recent dispatches

EDC, eCRF, eCOA and IWRS as One Regulated Data Flow: Who Owns the Source Record and Where ALCOA Breaks at the Seams

Clinical Trial Design and Management as One Quality-by-Design Chain: From Critical-to-Quality Factors to Risk-Based Oversight

Clinical Trial Site Monitoring: The Visit-Type Lifecycle (SSV, SIV, IMV, COV) and the SIV Enrollment Gate

The TMF Reference Model as a Tailoring Exercise: Mapping DIA/CDISC Zones to ICH E6(R3) Essential Records

Clinical Trial Close-Out Checklist: A Dependency-Gated Sequence Built on GCP and 21 CFR Part 312

The Monitoring Visit Report as Oversight Evidence: A GCP-Audit-Ready MVR, Not a Filled-In Form

Data Safety Monitoring Plan vs. Medical Monitoring Plan vs. DSMB Charter: Which One Your Trial Needs, Who Signs It, and How They Fit Together

Protocol Deviation Management: An Impact-Classified Triage-and-Timeline Workflow Under ICH E6(R3) and 21 CFR 312

Risk-Based Monitoring in Clinical Trials: The Quality-by-Design Chain That Decides Where a Monitor Goes

The archive

The Quality-by-Design Clinical Trial Protocol: Engineering Out Deviations with Critical-to-Quality Factors and a Defensible Schedule of Activities

The Protocol Deviation Log, Engineered: Columns, Classification, and the Timelines an Inspector Reads as Control

Clinical Trial Endpoints as a Pre-Locked Contract: Who May See Endpoint and Interim Data, When, and What Counts as a Deviation

CTMS vs eTMF: Which System Is the System of Record (and Why GCP Findings Live on That Boundary)

Choosing an eTMF System That Survives a GCP Inspection: A Sponsor's Defensibility Framework

Screen Failure in Clinical Trials: How to Calculate the Rate, Document It Under GCP, and Read It as a Critical-to-Quality Signal

There Is No FDA IND Database: What You Can Actually Look Up, and How the Form-1571 IND Clock Really Works

IRB Approval, Decoded: Pick Your Review Tier Before You Submit (Exempt, Expedited, or Full Board)

Types of Audits in Clinical Trials: A Risk-Mapped Framework for Inspection Readiness

Clinical Trial Registration on ClinicalTrials.gov: The Two Questions and Three Clocks That Decide Your Deadline

TMF vs ISF: An Ownership-and-Reconciliation Contract, Not a Location Table

CAPA in Clinical Trials: The Four-Gate Workflow That Closes a Finding and Keeps It Closed

Electronic Data Capture Software: The Four GCP and Part 11 Obligations That Decide Whether 'Compliant' Survives an Inspection

ICH GCP After E6(R3): What the July 2025 Standard Requires Now, and How It Maps to FDA 21 CFR 312

The Trial Master File Checklist That Survives an Inspection: Completeness, Timeliness, and Quality Over a Document List

Central vs. Local IRB: What a Reliance Agreement Moves, and the GCP Duties It Can Never Transfer

Vulnerable Populations in Clinical Research: A Triage-and-Safeguard Playbook (Not a List to Memorize)

Drug Accountability in Clinical Trials: Closing the Custody Chain Before the Inspector Opens the Log

From Word Template to Defensible Essential Document: Making an Informed Consent Form GCP-Compliant

Clinical Research Coordinator Responsibilities: A Delegation-Mapped Guide to Staying In Scope for an FDA Inspection

Remote Monitoring in Clinical Trials: An RBQM Method That Survives an Inspection, Not a COVID Stopgap

Medical Monitor Responsibilities in Clinical Trials: The Four Safety Decisions, Their Reporting Clocks, and the Records That Prove Them

FDA DSUR Guidance: The DIBD-Anchored Annual Filing That Consolidates Your IND Annual Report (Not a Template)

Protocol Feasibility Assessment as an ICH E8 Quality-by-Design Gate: Run It on the Draft, Before Lock

Clinical Trial Terminology, Grouped by Workflow and Stamped to ICH E6(R3) (2025)

Clinical Trial Sponsor Responsibilities: The Non-Delegable Oversight System Under ICH E6(R3)

The Clinical Trial Agreement, Decoded: A Clause-by-Clause Negotiator's Playbook for the GCP Duties You Cannot Sign Away

The Delegation of Authority Log: Who Did What, and Whether They Were Qualified To

Risk-Based Quality Management (RBQM) Under ICH E6(R3): Quality Designed In, Not Inspected In

The Clinical Study Report (CSR): ICH E3 Structure as a Reasoning Framework

The Clinical Monitoring Plan: A Risk-Based Blueprint, Not a Visit Schedule

SUSAR Reporting: Suspected, Unexpected, Serious, and the Clocks That Follow

Informed Consent in Clinical Trials: A Continuous Process, Not a Signature

Source Data Verification (SDV): Targeted, Risk-Based, and Paired With Source Data Review

Form FDA 1572: The Investigator's Binding Commitment, Not a Form-Fill

Adverse Event and SAE Reporting in Clinical Trials: One Decision Tree, Two Reporting Tracks

ALCOA and ALCOA+ Data Integrity in Clinical Trials: What the Acronym Actually Requires

The Trial Master File (TMF): An Inspection-Ready System, Not a Document Checklist

Protocol Deviations in Clinical Trials: Classify, Report, and Prevent Under ICH E6(R3)

Clinical Trial Budget Management: Building Compliant, Efficient Budgets in the ICH E6(R3) Era

Clinical Trial Delays Cost Prevention: Reducing Timeline Risk Without Compromising Compliance

Clinical Trial Milestones: Navigating FDA and ICH Regulatory Checkpoints for Successful Trial Execution

Audit Trail Requirements FDA 21 CFR Part 11 Clinical Research: What Regulators Expect and Why It Matters

Clinical Trial Management Guidelines: Applying FDA and ICH E6(R3) Standards for Modern, Risk-Based Trial Execution

Clinical Trial Project Management Challenges: Overcoming Regulatory Complexity, Enrollment Barriers, and Operational Risk

Clinical Study Startup Checklist: FDA and ICH E6(R3) Requirements to Prevent Costly Trial Delays

GCP SOP Template Clinical Trial Documentation ICH E6(R3): Building Compliant, Risk-Based SOPs for Modern Trials

Clinical Trial Project Management Guidelines: ICH GCP and FDA Requirements

ICH E6(R3) GCP Guidelines for Clinical Trials

Clinical Trial Compliance GCP Regulatory Guidelines: How to Meet FDA and ICH E6(R3) Expectations Without Derailing Your Study

CTMS Clinical Trial Management System Regulatory Compliance: Meeting FDA and 21 CFR Part 11 Requirements with Confidence

Clinical Trial Closeout Procedures: Ensuring FDA and ICH E6(R3) Compliance While Protecting Long-Term Data Integrity

CTMS vs EDC: Key Differences for Clinical Trial Management Teams

ICH E6(R3) Clinical Trial Risk Management Framework

FDA Clinical Trial Phases I II III IV Regulatory Guidance

Clinical Trial Compliance: Navigating ICH E6(R3) GCP Requirements in a Risk-Based Regulatory Era

CTMS and EDC Comparison as Clinical Data Management Systems

Vendor Management Clinical Trials CRO Oversight: Meeting FDA Expectations While Maintaining Control and Accountability

Clinical Site Selection Feasibility Checklist: FDA and ICH E6(R3) Criteria to Prevent Delays and Compliance Risk

ICH E6(R3) GCP Guidelines FDA EMA Implementation

Site Initiation Visit Checklist

Clinical Project Management GCP Pharmaceutical Research Guidelines

Clinical Trial Vendor Management: CRO Oversight and FDA Guidance

Clinical Trial Risk Management ICH E6(R3) Framework

FDA 21 CFR Part 11 Audit Trail Requirements Compliance

Site Initiation Visit Checklist GCP FDA Guidance